Scancell Holdings plc (SCLP) Ord GBP0.001
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Scancell shares jump on new antibody agreement with major biotech firm
12 June 2024 07:53
(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".
-
Scancell appoints healthcare finance veteran as new CFO
29 August 2023 14:27
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
-
Scancell to present positive recent findings at oncology summit
2 June 2023 13:18
(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago...
-
Scancell shares jump on positive cancer vaccine progress
21 February 2023 12:14
(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.
-
Scancell licenses Vaccitech IP for its next vaccine candidate
7 November 2022 09:29
(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.
-
Scancell enrols and doses first patient in latest cancer trial
31 October 2022 16:46
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of...
-
Scancell losses widen on expense of ongoing trials
28 October 2022 14:42
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to...
-
Scancell inks licensing deal with Nasdaq-traded Genmab
25 October 2022 14:34
(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal...
-
Scancell presents new, positive data on possible cancer therapies
23 September 2022 13:31
(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and...
-
Scancell developing 'promising' new cancer treatment approach
23 June 2022 12:38
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic...
-
Scancell updates protocol for UK trial in melanoma patients
15 June 2022 15:58
(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.
-
Scancell opens recruitment for cancer therapy trial
11 April 2022 13:10
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that its phase 1 and 2 clinical trial with 'Modi-1' is open for recruitment.
Company announcements Announcements
-
Result of Annual General Meeting
25 October 2024 15:26
Scancell Holdings
-
Holding(s) in Company
24 October 2024 07:00
Scancell Holdings
-
Scancell Appoints Dr Phil L’Huillier as CEO
22 October 2024 07:00
Scancell Holdings
-
Notice of AGM
1 October 2024 07:00
Scancell Holdings
-
Results Year Ended 30 April 2024
24 September 2024 07:00
Scancell Holdings
-
Notice of Final Results
18 September 2024 07:00
Scancell Holdings
-
Strategic Partnership with PharmaJet
17 September 2024 07:00
Scancell Holdings
-
Scancell to attend upcoming conferences
2 September 2024 07:00
Scancell Holdings
-
Scancell Appoints Dr Nermeen Varawalla as CMO
30 July 2024 07:17
Scancell Holdings
-
Scancell Appoints Dr Nermeen Varawalla as CMO
30 July 2024 07:00
Scancell Holdings
-
Update from iSCIB1+ Clinical Advisory Meeting
24 July 2024 07:00
Scancell Holdings
-
Appointment of Dr Florian Reinaud to the Board
10 July 2024 07:00
Scancell Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.